{"organizations": [], "uuid": "467b59b7ecd2d2c1507c0efbb3e665d134d4bda0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180502.html", "section_title": "Archive News &amp; Video for Wednesday, 02 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-indias-strides-shasun-gets-us-fda/brief-indias-strides-shasun-gets-u-s-fda-nod-for-cinacalcet-hydrochloride-tablets-idUSFWN1S900W", "country": "US", "domain_rank": 408, "title": "BRIEF-India's Strides Shasun Gets U.S. FDA Nod For Cinacalcet Hydrochloride Tablets", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-05-02T12:43:00.000+03:00", "replies_count": 0, "uuid": "467b59b7ecd2d2c1507c0efbb3e665d134d4bda0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-indias-strides-shasun-gets-us-fda/brief-indias-strides-shasun-gets-u-s-fda-nod-for-cinacalcet-hydrochloride-tablets-idUSFWN1S900W", "ord_in_thread": 0, "title": "BRIEF-India's Strides Shasun Gets U.S. FDA Nod For Cinacalcet Hydrochloride Tablets", "locations": [], "entities": {"persons": [{"name": "cinacalcet hydroc", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "puducherry", "sentiment": "none"}, {"name": "co", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "strides shasun ltd", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2 (Reuters) - Strides Shasun Ltd:\n* STRIDES SHASUN RECEIVES USFDA APPROVAL FOR CINACALCET HYDROCHLORIDE TABLETS\n* PRODUCT WILL BE MANUFACTURED AT COâ€™S ORAL DOSAGE FACILITY AT PUDUCHERRY\n* PRODUCT WILL BE MARKETED BY STRIDES PHARMA INC IN THE U.S. MARKET Source text - bit.ly/2re6dw0 Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://instagram.com/reuters/", "https://www.youtube.com/user/ReutersVideo", "https://bit.ly/2re6dw0"], "published": "2018-05-02T12:43:00.000+03:00", "crawled": "2018-05-03T12:34:46.006+03:00", "highlightTitle": ""}